Moderna's mRNA influenza vaccine receives $176m boost [Yahoo! Finance]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Yahoo! Finance
The RRPV Consortium, funded by the Biomedical Advanced Research and Development Authority (BARDA), operates under the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). The funding supports the late-stage development needed to license a pre-pandemic vaccine targeting the H5 influenza virus. The H5 subtype is known for causing severe avian influenza, with potential risks of spillover to humans. The project also encompasses other options to enhance preparedness for and response to future public health emergencies. In 2023, Moderna commenced a Phase I/II clinical trial to assess the safety and immune response of its investigational pandemic influenza vaccine, mRNA-1018, in adults aged 18 years and above. The study evaluates vaccine candidates for both H5 and H7 avian influenza strains. The trial results are anticipated during 2024 and will be vital in shaping the Phase III development strategy. Moderna
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNAAccesswire
- Arbutus Biopharma: Focused On HBV With A Potentially Huge Litigation 'Wildcard' [Seeking Alpha]Seeking Alpha
- U.S. Government Awards Moderna $176 Million Bird Flu Vaccine Contract [zero hedge]zero hedge
- Does H5N1 avian influenza have pandemic potential? [Yahoo! Finance]Yahoo! Finance
- Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More [Yahoo! Finance]Yahoo! Finance
MRNA
Earnings
- 5/2/24 - Beat
MRNA
Sec Filings
- 6/28/24 - Form 4
- 6/26/24 - Form 144
- 6/21/24 - Form 4
- MRNA's page on the SEC website